Genelux (GNLX) EBT Margin (2022 - 2024)

Genelux's (GNLX) quarterly EBT Margin came in at 118687.5% in Q1 2024, down 11305691.0% year-on-year from N/an in Q2 2023, and down 2007.91% quarter-over-quarter from 5630.59% in Q1 2023.

Genelux (GNLX) EBT Margin (2022 - 2024) Analysis & Trends

Genelux's EBT Margin history runs 3 years deep, the most recent figure standing at 118687.5% for Q1 2024.

  • On a quarterly basis, EBT Margin fell 11305691.0% year-over-year to 118687.5% in Q1 2024; TTM through Dec 2024 was 407125.0%, a 32545206.0% decrease from a year earlier, with the FY2025 full-year figure at 1387800.0%, down 24136250.0% from the prior year.
  • EBT Margin retreated to 118687.5% in Q1 2024 per GNLX's latest filing, from 5630.59% in the prior quarter.
  • Across five years, EBT Margin topped out at 54.63% in Q3 2022 and bottomed at 118687.5% in Q1 2024.
  • The 3-year median for EBT Margin is 2799.16% (2023), against an average of 31057.8%.
  • Biggest YoY gain for EBT Margin was 11305691 bps in 2024; the steepest drop was 11305691 bps in 2024.
  • Year by year, EBT Margin stood at 32.27% in 2022, then tumbled by 17548 bps to 5630.59% in 2023, then tumbled by 2008 bps to 118687.5% in 2024.
  • Per Business Quant, the three latest GNLX EBT Margin figures stand at 118687.5% (Q1 2024), 5630.59% (Q1 2023), and 32.27% (Q4 2022).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBT Margin (Qtr)
1 Oculis Holding AG 66,621.14 Bn 66,620.85 Bn - -
2 Nanobiotix 1,915.18 Bn 1,915.11 Bn - -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn - -
4 BeOne Medicines 471.27 Bn 466.48 Bn 1.35 Bn 17.13%
5 Vertex Pharmaceuticals 121.81 Bn 114.57 Bn 2.59 Bn 41.95%
6 Regeneron Pharmaceuticals 69.58 Bn 60.82 Bn 3.31 Bn 23.05%
7 Belite Bio 62.72 Bn 62.72 Bn - -
8 Argenx Se 55.51 Bn 50.33 Bn 1.41 Bn 34.77%
9 Revolution Medicines 37.35 Bn 37.35 Bn - -
10 Genelux 129.36 Mn 129.36 Mn - -

Historic Data

Download Data
DateValue
Mar 31, 2024 -118,687.50%
Mar 31, 2023 -5,630.59%
Dec 31, 2022 32.27%
Sep 30, 2022 54.63%